Premium
Clopidogrel pretreatment may reduce early acquired thrombocytopenia after transcatheter aortic valve replacement (TAVR)
Author(s) -
Ashley Kellan E.,
Hillegass William B.
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28569
Subject(s) - medicine , valve replacement , clopidogrel , cardiology , stenosis , myocardial infarction
Key Points Transcatheter aortic valve replacement (TAVR) causes early acquired thrombocytopenia on postoperative Days 1 and 2 in 30–50% of patients. While usually transient and rarely severe, early acquired thrombocytopenia is strongly associated with 30‐day and 1‐year post‐TAVR outcomes, including mortality. Observation from a prospective registry suggests pretreatment with the P2Y 12 receptor inhibitor clopidogrel before TAVR reduces the frequency and magnitude of early acquired thrombocytopenia. If a protective effect of clopidogrel pretreatment on early thrombocytopenia can be confirmed, then further study to determine if this translates into improved TAVR outcomes is warranted.